Turn Therapeutics Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Turn Therapeutics announced interim Phase 2 data (July 7, 2026) showing GX-03 achieved treatment separation in atopic dermatitis across a broader patient population than expected, including moderate-to-severe lesions with lower EASI scores (e.g., 61.5% vs 8.3% clear/almost-clear skin at Week 4). Based on findings, the company expanded Stage 2 enrollment to ~120–135 patients and expects completion by Q4 2026. Separately, Dr. Stephen Hahn (former FDA Commissioner) was appointed Executive Clinical and Regulatory Lead (May 18, 2026). Cash position: $10.3M as of June 30, 2026, funding operations into Q3 2027. The company also published first peer-reviewed preclinical data (May 27, 2026) and plans a Phase 2a HS study with first dosing targeted Q2 2027.
Why this rating
Interim efficacy data and regulatory leadership hire are meaningful for clinical-stage firm; $10.3M cash runway is adequate near-term but runway limited. Significance driven by de-risking of lead asset and credible regulatory pathway; moderated by early-stage, small absolute asset base.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.